Freely Filtered 028: Finerenone for diabetic kidney disease

1

Introduction

00:00 • 2min

2

Nephrology Fellows, Are You a PI in the Study?

01:30 • 2min

3

How Long Have You Been Getting Involved With This Clinical Trial?

03:46 • 5min

4

Are You on a Stable Dose?

08:17 • 4min

5

Is There a Risk of Hyperkalemia in a Study Like This?

12:45 • 2min

6

Is There a High Dropout of Potassium Binders?

14:24 • 4min

7

Type 4 RTA and Diabetic Board Questions Written in Four or Three Days Ago

18:34 • 2min

8

Is This the FDA Requirement for EGFR Changes?

20:18 • 2min

9

Are We Getting Better at Constructing These Trials?

22:08 • 3min

10

Is This Bayer's First Foray Into the Kidney World?

25:14 • 4min

11

Egfr

28:51 • 2min

12

Is There a Difference Between Primary and Secondary Composite Kidney Outcomes?

30:22 • 2min

13

Do You Know What's Going on With Finarinone?

32:09 • 2min

14

The Difference Between Fenerino and Spyrolactone

34:11 • 3min

15

Diabetic Nephropathy - Is There a Hemodynamic Effect?

37:14 • 3min

16

Do You Have Hyperkalemia in the Finarinone Study?

39:59 • 4min

17

Is There a Risk of Hyperkalemia in CKD?

44:09 • 6min

18

Diabetic Kidney Disease - Is There a Difference Between the Two?

49:45 • 5min

19

Nephrology Fellowship Match Day

54:22 • 2min

20

I'm the Worst Nephrology Fellow of Class in History

56:08 • 3min

21

The Renal Podcast

59:17 • 3min